Indexed In : Science Citation Index Expanded(SCIE), MEDLINE,
Pubmed/Pubmed Central, Elsevier Bibliographic, Google Scholar,
Databases(Scopus & Embase), KCI, KoreaMed, DOAJ
Gut and Liver is an international journal of gastroenterology, focusing on the gastrointestinal tract, liver, biliary tree, pancreas, motility, and neurogastroenterology. Gut atnd Liver delivers up-to-date, authoritative papers on both clinical and research-based topics in gastroenterology. The Journal publishes original articles, case reports, brief communications, letters to the editor and invited review articles in the field of gastroenterology. The Journal is operated by internationally renowned editorial boards and designed to provide a global opportunity to promote academic developments in the field of gastroenterology and hepatology. +MORE
Yong Chan Lee |
Professor of Medicine Director, Gastrointestinal Research Laboratory Veterans Affairs Medical Center, Univ. California San Francisco San Francisco, USA |
Jong Pil Im | Seoul National University College of Medicine, Seoul, Korea |
Robert S. Bresalier | University of Texas M. D. Anderson Cancer Center, Houston, USA |
Steven H. Itzkowitz | Mount Sinai Medical Center, NY, USA |
All papers submitted to Gut and Liver are reviewed by the editorial team before being sent out for an external peer review to rule out papers that have low priority, insufficient originality, scientific flaws, or the absence of a message of importance to the readers of the Journal. A decision about these papers will usually be made within two or three weeks.
The remaining articles are usually sent to two reviewers. It would be very helpful if you could suggest a selection of reviewers and include their contact details. We may not always use the reviewers you recommend, but suggesting reviewers will make our reviewer database much richer; in the end, everyone will benefit. We reserve the right to return manuscripts in which no reviewers are suggested.
The final responsibility for the decision to accept or reject lies with the editors. In many cases, papers may be rejected despite favorable reviews because of editorial policy or a lack of space. The editor retains the right to determine publication priorities, the style of the paper, and to request, if necessary, that the material submitted be shortened for publication.
Jihye Park1,2 , Jin Su Kim3 , Joo Hye Song4 , Kwangwoo Nam5 , Seong-Eun Kim6 , Eui Sun Jeong6 , Jae Hyun Kim7 , Seong Ran Jeon8
Correspondence to: Seong Ran Jeon
ORCID https://orcid.org/0000-0001-6970-9737
E-mail srjeon@schmc.ac.kr
Jihye Park and Jin Su Kim contributed equally to this work as first authors.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Gut Liver 2024;18(4):686-694. https://doi.org/10.5009/gnl240030
Published online May 10, 2024, Published date July 15, 2024
Copyright © Gut and Liver.
Background/Aims: Despite advances in imaging and endoscopic technology, diagnostic modalities for small bowel tumors are simultaneously performed. We investigated the discrepancy rate between each modality and predictive factors of discrepancy in patients with definite small bowel tumors.
Methods: Data of patients with definite small bowel tumors who underwent both device-assisted enteroscopy (DAE) and computed tomography (CT) were retrieved from web-based enteroscopy registry database in Korea. Predictive risk factors associated with discrepancy were analyzed using logistic regression analysis.
Results: Among 998 patients, 210 (21.0%) were diagnosed with small bowel tumor using DAE, in 193 patients with definite small bowel tumor, DAE and CT were performed. Of these patients, 12 (6.2%) showed discrepancy between examinations. Among 49 patients who underwent DAE and video capsule endoscopy (VCE) examination, 13 (26.5%) showed discrepancy between examinations. No significant independent risk factors were associated with concordance between DAE and CT in multivariate logistic regression analysis among the patients. In a multivariate logistic regression analysis, red blood cell transfusion was negatively associated with concordance between DAE and VCE in patients with small bowel tumor (odds ratio, 0.163; 95% confidence interval, 0.026 to 1.004; p=0.050).
Conclusions: For small bowel tumors, the discrepancy rate between DAE and CT was 6.2%, and 26.5% between DAE and VCE. Despite developments in cross-sectional imaging (VCE and DAE modalities), discrepancies still exist. For small bowel bleeding that require significant transfusion while showing insignificant VCE findings, DAE should be considered as the next diagnostic approach, considering the possibility of missed small bowel tumor.
Keywords: Balloon enteroscopy, Tomography, X-ray computed, Capsule endoscopy, Neoplasms
Small bowel tumors are very rare, and they account for 1% to 3% of all gastrointestinal neoplasms.1 The rapid transit time of the small bowel and its liquid contents, which reduce the exposure of ingested carcinogen to its mucosa, relative sterility of the small bowel compared to that of the colon, and its intrinsic protective immune system could explain the extremely low frequency of small bowel tumors.2 The diagnosis of small bowel tumors is often challenging, owing to their rarity and non-specific clinical features.3 Moreover, majority of patients with small bowel tumors are asymptomatic or present with only non-specific symptoms when they have advanced disease.4,5 Additionally, poor accessibility of the small bowel due to very long anatomical structure (600 to 700 cm) and inaccessibility of the diagnostic modalities also contribute to the difficulty in diagnosing small bowel tumors.6 Nevertheless, the incidence of these tumors has been increasing in the last few decades, thereby keeping pace with remarkable advances in diagnostic modalities.7
Various diagnostic modalities, including cross-sectional imaging and endoscopy, are simultaneously performed in patients suspected of having small bowel tumors; this is because a definite diagnosis is difficult with a single diagnostic method.8 Cross-sectional imaging modalities, including computed tomography (CT) and magnetic resonance imaging, play a central role in the diagnosis of small bowel tumors because they allow visualization of the entire gastrointestinal tract, as well as extramural lesions.9 Additionally, video capsule endoscopy (VCE), which is the first line diagnostic modality for small bowel bleeding, may aid in the diagnosis of small bowel tumors, although missing rates and capsule retention must be carefully considered.10,11 Device-assisted enteroscopy (DAE) allows clinicians to directly visualize small bowel tumors, identify their extent and location, obtain tissue samples, and perform therapeutic interventions.12,13 DAE is an effective diagnostic and therapeutic method, but it is more labor intensive, requires experienced endoscopists and is difficult to evaluate the entire small bowel. Despite advances in imaging and endoscopic technology, discrepancy in diagnosis occurs for each modality. Depending on the characteristics of the diagnostic modality, this is an inevitable event.
In this study, we aimed to determine the discrepancy rates between DAE and CT, and between DAE and VCE for small bowel tumors confirmed by DAE. Additionally, we analyzed the risk factors associated with concordance rates between DAE and CT, and between DAE and VCE for small bowel tumors.
This retrospective, multicenter cohort study was conducted using database of the Korean Association for the Study of Intestinal Disease web-based enteroscopy registry (https://enteroscopy.inforang.com/intro/intro.html) from 30 medical centers in South Korea between October 2015 and June 2023. Data were collected anonymously via standardized electronic case report form and managed in the Small Intestinal Research Group under the Korean Association for the Study of Intestinal Disease. Of 998 patients, 210 (21.0%) were diagnosed with small bowel tumors using DAE. A total of 193 patients diagnosed with definite small bowel tumor and underwent both DAE and CT were included in this study. Of the 193 patients, 49 underwent VCE (Fig. 1). Exclusion criteria were as follows: (1) age <18 years old; (2) no evidence of small bowel tumor in DAE and/or CT; (3) either CT or DAE was not performed; (4) uncertain diagnosis despite various diagnostic modalities; or (5) incomplete electronic medical records. The study protocol was approved by the Institutional Review Board and Hospital Research Ethics Committee of each facility (IRB number: 1-2016-0004). Written informed consent was waived.
Double (EN-450P5, T5 or EN-530T; Fujinon Inc., Saitama, Japan) and single (SIF-Q180; Olympus America Inc., Center Valley, PA, USA) balloon enteroscopes, both of which are available in South Korea, were used for enteroscopic examinations. Furthermore, for DAE using the anal approach, the patients underwent bowel preparation with at least 2 L of polyethylene glycol solution the day before the procedure. The route of DAE insertion was determined based on the location of the lesion, according to the results of previous examinations. All procedures were performed in a fluoroscopy unit, with patients undergoing conscious to deep sedation (established by endoscopists), according to each center’s sedation protocols. The PillCam SB video (SB1, SB2, and SB3; Given Imaging, Yokneam, Israel) and MiroCam (IntroMedic, Seoul, South Korea) were used for capsule endoscopy. Polyethylene glycol solution (2–4 L) was administered before the examination for cleansing and enhancement of visual clarity. Video findings were interpreted by experienced gastroenterologists at each center. We included all patients that underwent multiphasic CT and CT enterography.
The following data were collected from electronic medical records: age, sex, smoking history, alcohol history, Charlson Comorbidity Index, intestinal surgery history, indication of diagnostic test, levels of hemoglobin, albumin, transfusion of red blood cell (RBC), and the size, number, location, and final diagnosis of small bowel tumors. The Charlson Comorbidity Index was used for the assessment of comorbidity level.14
The small bowel tumors that were definite on DAE and/or CT were defined, according to the interpretation by experienced gastroenterologists and radiologists. Primary endpoint was discordance rates between DAE and CT, and between DAE and VCE. A discordance was defined when a small bowel tumor was described in DAE but its presence was not described in CT or VCE. Additionally, in DAE, it was described as a small bowel tumor, but when CT or VCE showed other findings such as ulcers/vascular lesions, it was defined as a discordance. Additionally, secondary endpoint was independent risk factors associated with the discordance between DAE and VCE, and between DAE and CT for small bowel tumors. Additionally, secondary endpoint was independent risk factors associated with the discordance between DAE and VCE, and between DAE and CT for small bowel tumors.
The mean and standard deviation or median and range were calculated for all continuous variables, as appropriate. Multivariate logistic regression analyses were performed to identify independent factors affecting discordance with adjustment for multiple variables. Variables in univariate analysis, with a p-value of ≤0.05, were included in the multivariate analysis. Moreover, a p-value of ≤0.05 was considered statistically significant. All statistical analyses were performed using Statistical Package for Social Sciences (SPSS version 23.0; SPSS Inc., Armonk, NY, USA).
The mean age of diagnosis was 54.3±13.7 years, and 57.5% of the patients were men. Thirty-nine patients (20.2%) and 47 patients (24.5%) had a history of smoking and alcohol consumption, respectively. The mean Charlson Comorbidity Index was 0.7±1.2, and 45 patients (23.3%) had a history of intestinal surgery. The indication of DAE was abnormal radiologic findings (40.9%), polyposis syndrome (17.6%), overt gastrointestinal bleeding (17.1%), occult gastrointestinal bleeding (2.1%), symptoms, such as abdominal pain, nausea, or vomiting (10.4%), intestinal obstruction (6.7%), and therapeutics (5.2%). The mean hemoglobin level was 11.4±2.6 g/dL, and the mean albumin level was 3.9±0.8 g/dL. Forty patients (20.7%) required RBC transfusion, and the mean volume of RBC was 0.8±2.1 units. Forty-four patients (22.8%) underwent per oral DAE, 141 (73.1%) underwent per anal DAE, and eight (4.1%) underwent both per oral DAE and per anal DAE. Multiphasic CT was performed in 132 (68.4%), and 61 (31.6%) underwent CT enterography. The mean size of the small bowel tumors measured on CT was 25.4±15.2 mm, and 166 patients (85.0%) had single tumor. Locations of the small bowel tumors were the duodenum (10.4%), proximal jejunum (34.2%), mid jejunum (18.7%), distal jejunum (10.9%), proximal ileum (4.7%), mid ileum (4.7%), and distal ileum (15.5%). Final diagnoses of the small bowel tumors were lymphoma (19.7%), hamartoma (18.7%), gastrointestinal stromal tumor (18.1%), ectopic pancreas (11.9%), metastasis (11.4%), lipoma (5.2%), adenocarcinoma (4.7%), benign polyp (3.6%), carcinoid (2.1%), amyloidosis (1.6%), leiomyoma (1.0%), lymphangioma (1.0%), schwannoma (0.5%), and duplication cyst (0.5%).
Of the 193 patients that underwent DAE and CT examinations, 12 (6.2%) showed discrepancy between the examinations. Male patients were more in number in a discordance group compared to those in a concordance group between DAE and CT (91.7% vs 55.2%, respectively, p=0.015). Furthermore, overt gastrointestinal bleeding was frequent in the discordance group compared to that in the concordance group between DAE and CT (41.7% vs 15.5%, respectively, p=0.035) (Table 1). Carcinoid was frequent in the discordance group compared to that in the concordance group (25.0% vs 0.6%), and amyloidosis was frequent in the discordance group compared to that in the concordance group between DAE and CT (16.7% vs 0.6%) (Table 2). Univariate logistic regression analyses were performed to determine the risk factors associated with the concordance between DAE and CT. Furthermore, female sex was positively associated with the concordance between DAE and CT in patients with small bowel tumors (odds ratio [OR], 8.910; 95% confidence interval [CI], 1.127 to 70.467; p=0.038) (Table 3). Alcohol history (OR, 0.293; 95% CI, 0.090 to 0.957; p=0.042) and overt bleeding (OR, 0.256; 95% CI, 0.076 to 0.865; p=0.028) were negatively associated with the concordance between DAE and CT in patients with small bowel tumor (Table 3). There were no significant independent risk factors in the multivariate regression analysis.
Table 1. Baseline Characteristics Associated with Discordance between DAE and CT of Small Bowel Tumors
Variable | Total (n=193) | Discordance (n=12) | Concordance (n=181) | p-value* |
---|---|---|---|---|
Age, yr | 54.3±13.7 | 59.4±12.4 | 54.2±16.6 | 0.288 |
Sex | 0.015 | |||
Male | 111 (57.5) | 11 (91.7) | 100 (55.2) | |
Female | 82 (42.5) | 1 (8.3) | 81 (44.8) | |
Smoking | 39 (20.2) | 3 (25.0) | 36 (19.9) | 0.711 |
Alcohol | 47 (24.4) | 6 (50.0) | 41 (23.7) | 0.074 |
Charlson Comorbidity Index | 0.7±1.2 | 0.5±1.0 | 0.7±1.4 | 0.563 |
Intestinal surgery history | 45 (23.3) | 0 | 45 (24.9) | 0.072 |
Indication of diagnostic test | ||||
Abnormal radiologic images | 79 (40.9) | 4 (33.3) | 75 (41.4) | 0.764 |
Polyposis | 34 (17.6) | 1 (8.3) | 33 (18.2) | 0.695 |
Overt bleeding | 33 (17.1) | 5 (41.7) | 28 (15.5) | 0.035 |
Occult bleeding | 4 (2.1) | 0 | 4 (2.2) | 1.000 |
Non-specific symptoms | 20 (10.4) | 2 (16.7) | 18 (9.9) | 0.359 |
Obstruction | 13 (6.7) | 0 | 13 (7.2) | 1.000 |
Others (therapeutics) | 10 (5.2) | 0 | 10 (5.5) | 1.000 |
Hemoglobin, g/dL | 11.4±2.6 | 10.9±2.7 | 11.5±2.5 | 0.448 |
Albumin, g/dL | 3.9±0.8 | 3.7±0.8 | 3.9±0.7 | 0.244 |
Red blood cell transfusion | 40 (20.7) | 4 (33.3) | 36 (19.9) | 0.276 |
Characteristics of small bowel tumor | ||||
Tumor size, mm | 25.4±15.2 | 25.0±14.0 | 25.4±17.1 | 0.947 |
Single tumor | 166 (85.0) | 10 (83.3) | 156 (86.2) | 0.970 |
Tumor location | 0.664 | |||
Duodenum | 20 (10.4) | 1 (8.3) | 19 (10.5) | |
Proximal jejunum | 66 (34.2) | 3 (25.0) | 63 (34.8) | |
Mid jejunum | 36 (18.7) | 2 (16.7) | 34 (18.8) | |
Distal jejunum | 21 (10.9) | 2 (16.7) | 19 (10.5) | |
Proximal ileum | 9 (4.7) | 0 | 9 (5.0) | |
Mid ileum | 9 (4.7) | 0 | 9 (5.0) | |
Distal ileum | 30 (15.5) | 2 (16.7) | 28 (15.5) |
Data are presented as mean±SD or number (%).
DAE, device-assisted enteroscopy; CT, computed tomography.
*p-value for comparing discordance and accordance groups: statistically significant, p<0.05.
Table 2. Final Diagnosis of Small Bowel Tumor According to the Discordance between DAE and CT
Variable | Discordance (n=12) | Concordance (n=181) |
---|---|---|
Lymphoma | 3 (25.0) | 35 (19.3) |
Hamartoma | 0 | 36 (19.9) |
Gastrointestinal stromal tumor | 2 (16.7) | 33 (18.2) |
Ectopic pancreas | 0 | 23 (12.7) |
Metastasis | 0 | 22 (12.2) |
Lipoma | 0 | 10 (5.5) |
Adenocarcinoma | 0 | 9 (5.0) |
Benign polyp | 2 (16.7) | 5 (2.8) |
Carcinoid | 3 (25.0) | 1 (0.6) |
Amyloidosis | 2 (16.7) | 1 (0.6) |
Leiomyoma | 0 | 2 (1.1) |
Lymphangioma | 0 | 2 (1.1) |
Schwannoma | 0 | 1 (0.6) |
Duplication cyst | 0 | 1 (0.6) |
Data are presented as number (%).
DAE, device-assisted enteroscopy; CT, contrast tomography.
Table 3. Logistic Regression Analysis for Concordance between DAE and CT in Patients with Small Bower Tumor
Variable | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|
OR (95% CI) | p-value* | OR (95% CI) | p-value* | ||
Age | 0.980 (0.944–1.017) | 0.289 | |||
Female sex | 8.910 (1.127–70.467) | 0.038 | 5.617 (0.652–48.429) | 0.116 | |
Smoking | 0.745 (0.192–2.892) | 0.670 | |||
Alcohol | 0.293 (0.090–0.957) | 0.042 | 0.498 (0.144–1.723) | 0.271 | |
Charlson Comorbidity Index (≥2) | 1.606 (0.339–7.609) | 0.551 | |||
Indication of diagnostic test | |||||
Abnormal radiologic images | 1.415 (0.411–4.871) | 0.582 | |||
Polyposis | 2.453 (0.306–19.664) | 0.398 | |||
Overt bleeding | 0.256 (0.076–0.865) | 0.028 | 0.396 (0.113–1.394) | 0.149 | |
Non-specific symptoms | 0.552 (0.112–2.719) | 0.465 | |||
Hemoglobin | 1.096 (0.865–1.368) | 0.447 | |||
Albumin | 1.586 (0.728–3.459) | 0.246 | |||
Red blood cell transfusion | 0.497 (0.142–1.741) | 0.274 | |||
Characteristics of small bowel tumor | |||||
Tumor size | 1.001 (0.961–1.044) | 0.946 | |||
Single tumor | 1.062 (0.762–1.480) | 0.723 | |||
Tumor location | |||||
Duodenum | 1.000 (reference) | ||||
Proximal jejunum | 1.105 (1.109–11.253) | 0.933 | |||
Mid jejunum | 0.895 (0.076–10.528) | 0.930 | |||
Distal jejunum | 0.500 (0.042–5.990) | 0.584 | |||
Proximal ileum | 0.999 (NA) | 0.999 | |||
Mid ileum | 0.237 (0.019–2.968) | 0.264 | |||
Distal ileum | 0.737 (0.062–8.712) | 0.809 |
DAE, device-assisted enteroscopy; CT, contrast tomography; OR, odds ratio; CI, confidence interval; NA, not applicable.
*p-value for comparing discordance and accordance groups: statistically significant, p<0.05.
Of the 49 patients that underwent DAE and VCE examinations, 13 (26.5%) showed discrepancy between the examinations. The discordance group was older compared to the concordance group between DAE and VCE (57.4 years vs 47.2 years, respectively, p=0.049) (Table 4). Overt gastrointestinal bleeding was frequent (53.8% vs 19.4%, respectively, p=0.031), hemoglobin level was lower (9.6 g/dL vs 11.7 g/dL, respectively, p=0.003), albumin level was lower (3.5 g/dL vs 4.1 g/dL, respectively, p=0.007), and RBC transfusion was frequent (69.2% vs 19.4%, respectively, p=0.002) in the discordance group compared to that of the concordance group between DAE and VCE (Table 4). Gastrointestinal stromal tumor was frequent in the discordance group compared to that of the concordance group (61.5% vs 8.3%) between DAE and VCE (Table 5). Univariate logistic regression analyses were performed to determine the risk factors associated with the concordance between DAE and VCE. Overt bleeding (OR, 0.207; 95% CI, 0.053 to 0.812; p=0.024) and RBC transfusion (OR, 0.107; 95% CI, 0.025 to 0.452; p=0.002) were negatively associated with the concordance between DAE and VCE in patients with small bowel tumors (Table 6). Higher albumin level was positively associated with the concordance between DAE and VCE in patient with small bowel tumors (OR, 3.214; 95% CI, 1.201 to 8.603; p=0.020) (Table 6). In the multivariate regression analysis, RBC transfusion was negatively associated with the concordance between DAE and VCE in patients with small bowel tumors (OR, 0.163; 95% CI, 0.026 to 1.004; p=0.050) (Table 6).
Table 4. Baseline Characteristics Associated with Discordance between DAE and VCE of Small Bowel Tumors
Variable | Total (n=49) | Discordance (n=13) | Concordance (n=36) | p-value* |
---|---|---|---|---|
Age, yr | 49.9±15.5 | 57.4±13.5 | 47.2±16.2 | 0.049 |
Sex | 0.333 | |||
Male | 27 (55.1) | 9 (69.2) | 18 (50.0) | |
Female | 22 (44.9) | 4 (30.8) | 18 (50.0) | |
Smoking | 7 (14.3) | 2 (15.4) | 5 (13.9) | 1.000 |
Alcohol | 12 (24.5) | 2 (15.4) | 10 (27.8) | 0.474 |
Charlson's Comorbidity Index | 0.5±1.0 | 0.6±1.1 | 0.5±0.9 | 0.657 |
Intestinal surgery history | ||||
Indication of diagnostic test | ||||
Abnormal radiologic images | 11 (22.4) | 2 (15.4) | 9 (25.0) | 0.703 |
Polyposis | 13 (26.5) | 1 (7.7) | 12 (33.3) | 0.140 |
Overt bleeding | 14 (28.6) | 7 (53.8) | 7 (19.4) | 0.031 |
Occult bleeding | 2 (4.1) | 2 (15.4) | 0 | 0.066 |
Non-specific symptoms | 4 (8.2) | 1 (7.7) | 3 (8.3) | 1.000 |
Others (therapeutics) | 5 (10.2) | 0 | 5 (13.9) | 0.306 |
Hemoglobin, g/dL | 11.1±2.7 | 9.6±3.0 | 11.7±2.2 | 0.003 |
Albumin, g/dL | 3.9±0.7 | 3.5±1.0 | 4.1±0.5 | 0.007 |
Red blood cell transfusion | 16 (32.7) | 9 (69.2) | 7 (19.4) | 0.002 |
Characteristics of small bowel tumor | ||||
Tumor size, mm | 24.0±12.5 | 30.0±14.4 | 21.8±10.9 | 0.107 |
Single tumor | 35 (71.4) | 13 (100.0) | 22 (66.1) | 0.314 |
Tumor location | 0.226 | |||
Proximal jejunum | 15 (30.6) | 3 (23.1) | 12 (33.3) | |
Mid jejunum | 15 (30.6) | 6 (46.2) | 9 (25.0) | |
Distal jejunum | 5 (10.2) | 2 (15.4) | 3 (8.3) | |
Proximal ileum | 4 (8.1) | 2 (15.4) | 2 (5.6) | |
Mid ileum | 5 (10.2) | 0 | 5 (13.9) | |
Distal ileum | 5 (10.2) | 0 | 5 (13.9) |
Data are presented as mean±SD or number (%).
DAE, device-assisted enteroscopy; VCE, video capsule endoscopy.
*p-value for comparing discordance and accordance groups: statistically significant, p<0.05.
Table 5. Final Diagnosis of Small Bowel Tumor According to the Discordance between DAE and VCE
Variable | Discordance (n=13) | Concordance (n=36) |
---|---|---|
Hamartoma | 0 | 15 (41.7) |
Gastrointestinal stromal tumor | 8 (61.5) | 3 (8.3) |
Lymphoma | 1 (7.7) | 8 (22.2) |
Ectopic pancreas | 1 (7.7) | 4 (11.1) |
Benign polyp | 0 | 2 (5.6) |
Lipoma | 1 (7.7) | 1 (2.8) |
Adenocarcinoma | 0 | 1 (2.8) |
Carcinoid | 1 (7.7) | 0 |
Amyloidosis | 0 | 1 (2.8) |
Lymphangioma | 1 (7.7) | 0 |
Schwannoma | 0 | 1 (2.8) |
Data are presented as number (%).
DAE, device-assisted enteroscopy; VCE, video capsule endoscopy.
Table 6. Logistic Regression Analysis for Concordance between DAE and VCE in Patients with Small Bower Tumor
Variable | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|
OR (95% CI) | p-value* | OR (95% CI) | p-value* | ||
Age | 0.957 (0.914–1.001) | 0.057 | |||
Female sex | 2.250 (0.585–8.652) | 0.238 | |||
Smoking | 0.887 (0.150–5.251) | 0.895 | |||
Alcohol | 2.115 (0.397–11.281) | 0.380 | |||
Charlson Comorbidity Index (≥2) | 2.897 (0.321–26.158) | 0.344 | |||
Indication of diagnostic test | |||||
Abnormal radiologic images | 1.833 (0.340–9.886) | 0.481 | |||
Polyposis | 6.000 (0.696–51.740) | 0.103 | |||
Overt bleeding | 0.207 (0.053–0.812) | 0.024 | 0.922 (0.141–6.024) | 0.932 | |
Non-specific symptoms | 1.091 (0.103–11.527) | 0.942 | |||
Hemoglobin | 1.470 (1.110–1.946) | 0.007 | |||
Albumin | 3.214 (1.201–8.603) | 0.020 | 2.046 (0.752–5.583) | 0.161 | |
Red blood cell transfusion | 0.107 (0.025–0.452) | 0.002 | 0.163 (0.026–1.004) | 0.050 | |
Characteristics of small bowel tumor | |||||
Tumor size (mm) | 0.946 (0.882–1.014) | 0.118 | |||
Single tumor | NA (NA) | 0.999 | |||
Tumor location | |||||
Proximal jejunum | 1.000 (reference) | ||||
Mid jejunum | 0.375 (0.073–1.920) | 0.239 | |||
Distal jejunum | 0.375 (0.042–3.355) | 0.380 | |||
Proximal ileum | 0.250 (0.024–2.577) | 0.244 | |||
Mid ileum | 0.999 (NA) | 0.999 | |||
Distal ileum | 0.999 (NA) | 0.999 |
DAE, device-assisted enteroscopy; VCE, video capsule endoscopy; OR, odds ratio; CI, confidence interval; NA, not applicable.
*p-value for comparing discordance and accordance groups: statistically significant, p<0.05.
This study was conducted with the assumption that despite advances in cross-sectional and VCE imaging, there will still be discrepancies between DAE and other modalities for small bowel tumors. In fact, the results showed that there was a discordance of 6.2% in DAE and CT, and 26.5% in DAE and VCE. Despite the development of novel techniques, the single diagnostic approach is not sufficient for a definite diagnosis of small bowel tumors.15 Cross-sectional imaging, DAE, and VCE are the most commonly used techniques for detecting small bowel tumors, and they have complementary advantages and disadvantages, and various optimal sequence of diagnostic techniques could be suggested.16,17 Therefore, identifying the discrepancy of diagnostic modalities and finding associated factors is of great help in clinical practice.18
Cross-sectional imaging, including CT and magnetic resonance imaging, could be recommended for the initial investigation of patients suspected of having small bowel tumors because it is noninvasive, as they can visualize the entire small intestine and surrounding structures.19,20 Moreover, in clinical settings, CT is the most commonly used cross-sectional imaging. However, CT enterography with luminal distention or magnetic resonance enterography without radiation is preferred for follow-up examination.16 In patients with suspected small bowel tumors, DAE could be performed for diagnostic purpose to reach histological confirmation by acquisition of biopsy sample and/or therapeutic purposes, such as hemostasis, polypectomy, or stent insertion.21 In our study, the discrepancy rate of small bowel tumors between DAE and CT was 6.2%, and the concordance between DAE and CT was quite high. In a previous study of 68 patients, small bowel tumors were detected in 58 and 61 patients using CT and DAE (discrepancy: 4.4%), respectively, which is similar to those in our study.22 Additionally, there were no significant risk factors related to the discordance between CT and DAE, including size of small bowel tumors. Nevertheless, cross-sectional imaging may have decreased the sensitivity for small-sized small bowel tumors that are <10 mm, and caution is necessary because the discrepancy between CT and VCE was relatively high for carcinoid and amyloidosis.23-25 Primary carcinoid tumor in the small bowel is often not visible due to a small size often <10 mm at initial evaluation using CT.23 Additionally, CT findings of small intestinal amyloidosis are non-specific and diverse.24,25 Additionally, in our study, patients who had CT but did not have DAE (e.g., cases thought to be small benign lesions) were excluded from the study; therefore, it should be noted that the missing rate in actual CT may be higher.
Regarding VCE, the discrepancy rate between DAE and VCE was 26.5% for small bowel tumors, which is higher than that between DAE and CT. The reason for the discrepancy between DAE and VCE is that VCE itself has some limitations due to relatively high false negative risks and false positive risks.26,27 Missing rate of VCE for solitary small bowel lesion was 10% to 12% in a previous studies because of rapid transit time in the small bowel, which is dependent on reading mode, lesion type, reader experience, and timing.28-31 Most of the small bowel tumors missed by VCE were located in the proximal jejunum because of rapid transfer velocity due to bowel peristalsis.22 Additionally, small bowel tumors cannot be reliably differentiated using VCE because the surface of benign and malignant small bowel tumors are not specific, which requires complementary diagnostic tests, such as DAE.32,33 In our study, gastrointestinal stromal tumor was frequent in the discordance group between DAE and VCE, and RBC transfusion was associated with discordance between DAE and VCE in patients with small bowel tumor in the multivariate analysis. Zagorowicz et al.34 reported the characteristics of small bowel tumors detected using VCE and identified missed tumors, and of 139 patients, two small bowel gastrointestinal stromal tumors and one mesenteric tumor were missed by VCE, which were found during a follow-up period. In patients with small bowel bleeding, they required transfusion and normal/insignificant VCE, and the risk of missing a tumor in the small bowel can be underestimated.34 Therefore, DAE should be considered as the next diagnostic approach when clinical symptoms strongly suggest small bowel bleeding. In summary, VCE itself is affected not only by rapid transition time of the small intestine but also by non-specific characteristics of small intestine tumors, resulting in a relatively high risk of false negative and positive risks. Therefore, clinicians should pay attention to when performing or interpreting VCE and consider DAE in patients with a negative VCE and high clinical suspicion (e.g., small bowel bleeding or unexplained iron deficient anemia).
This is a large multicenter study with enough sample using the Korean Association for the Study of Intestinal Disease web-based enteroscopy registry database from 30 medical centers in South Korea. Additionally, we could analyze the discrepancy rate and risk factors between DAE and CT and between DAE and VCE for small bowel tumors confirmed by DAE. Nevertheless, there are some limitations in our study. First, if DAE is requested due to suspicion of progressive disease, the actual discrepancy rate between DAE and CT may be higher in this study due to selection bias. In addition, since CT is generally taken first and DAE is often performed when abnormality of imaging is detected, selection bias may have occurred, and as a result, the discrepancy rate between DAE and CT may have been evaluated as low. Second, we could not suggest a diagnostic yield for each modality because we enrolled only patients with definite diagnosis of small bowel tumors who underwent DAE and CT. Third, the sample size of patients who underwent DAE and VCE was too small.
In conclusion, our study showed that the discrepancy rate between DAE and CT was 6.2%, and the discrepancy rate between DAE and VCE was 26.5% of small bowel tumors. Despite developments in cross-sectional imaging, including VCE and DAE modalities, discrepancies still exist. In patients with small bowel bleeding who required significant transfusion while showing insignificant VCE findings, DAE should be considered as the next diagnostic approach due to the possibility of missing a diagnosis of small bowel tumor.
This work was supported by the Soonchunhyang University Research Fund.
No potential conflict of interest relevant to this article was reported.
Conception and design: J.P., J.S.K., S.R.J. Data acquisition: J.S.K., J.H.S., K.N., S.E.K., E.S.J., J.H.K. Data analysis and interpretation: J.P. Drafting of the manuscript: J.P. Critical revision of the manuscript for important intellectual content: S.R.J. Approval of final manuscript: all authors.
Gut and Liver 2024; 18(4): 686-694
Published online July 15, 2024 https://doi.org/10.5009/gnl240030
Copyright © Gut and Liver.
Jihye Park1,2 , Jin Su Kim3 , Joo Hye Song4 , Kwangwoo Nam5 , Seong-Eun Kim6 , Eui Sun Jeong6 , Jae Hyun Kim7 , Seong Ran Jeon8
1Department of Internal Medicine and 2Institute of Gastroenterology, Severance Hospital, Yonsei University College of Medicine, Seoul, Korea; 3Department of Internal Medicine, Eunpyeong St. Mary’s Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea; 4Department of Internal Medicine, Konkuk University Medical Center, Konkuk University School of Medicine, Seoul, Korea; 5Department of Gastroenterology, Dankook University Hospital, Dankook University College of Medicine, Cheonan, Korea; 6Department of Internal Medicine, Ewha Womans University College of Medicine, Seoul, Korea; 7Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea; 8Institute for Digestive Research, Digestive Disease Center, Soonchunhyang University College of Medicine, Seoul, Korea
Correspondence to:Seong Ran Jeon
ORCID https://orcid.org/0000-0001-6970-9737
E-mail srjeon@schmc.ac.kr
Jihye Park and Jin Su Kim contributed equally to this work as first authors.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Background/Aims: Despite advances in imaging and endoscopic technology, diagnostic modalities for small bowel tumors are simultaneously performed. We investigated the discrepancy rate between each modality and predictive factors of discrepancy in patients with definite small bowel tumors.
Methods: Data of patients with definite small bowel tumors who underwent both device-assisted enteroscopy (DAE) and computed tomography (CT) were retrieved from web-based enteroscopy registry database in Korea. Predictive risk factors associated with discrepancy were analyzed using logistic regression analysis.
Results: Among 998 patients, 210 (21.0%) were diagnosed with small bowel tumor using DAE, in 193 patients with definite small bowel tumor, DAE and CT were performed. Of these patients, 12 (6.2%) showed discrepancy between examinations. Among 49 patients who underwent DAE and video capsule endoscopy (VCE) examination, 13 (26.5%) showed discrepancy between examinations. No significant independent risk factors were associated with concordance between DAE and CT in multivariate logistic regression analysis among the patients. In a multivariate logistic regression analysis, red blood cell transfusion was negatively associated with concordance between DAE and VCE in patients with small bowel tumor (odds ratio, 0.163; 95% confidence interval, 0.026 to 1.004; p=0.050).
Conclusions: For small bowel tumors, the discrepancy rate between DAE and CT was 6.2%, and 26.5% between DAE and VCE. Despite developments in cross-sectional imaging (VCE and DAE modalities), discrepancies still exist. For small bowel bleeding that require significant transfusion while showing insignificant VCE findings, DAE should be considered as the next diagnostic approach, considering the possibility of missed small bowel tumor.
Keywords: Balloon enteroscopy, Tomography, X-ray computed, Capsule endoscopy, Neoplasms
Small bowel tumors are very rare, and they account for 1% to 3% of all gastrointestinal neoplasms.1 The rapid transit time of the small bowel and its liquid contents, which reduce the exposure of ingested carcinogen to its mucosa, relative sterility of the small bowel compared to that of the colon, and its intrinsic protective immune system could explain the extremely low frequency of small bowel tumors.2 The diagnosis of small bowel tumors is often challenging, owing to their rarity and non-specific clinical features.3 Moreover, majority of patients with small bowel tumors are asymptomatic or present with only non-specific symptoms when they have advanced disease.4,5 Additionally, poor accessibility of the small bowel due to very long anatomical structure (600 to 700 cm) and inaccessibility of the diagnostic modalities also contribute to the difficulty in diagnosing small bowel tumors.6 Nevertheless, the incidence of these tumors has been increasing in the last few decades, thereby keeping pace with remarkable advances in diagnostic modalities.7
Various diagnostic modalities, including cross-sectional imaging and endoscopy, are simultaneously performed in patients suspected of having small bowel tumors; this is because a definite diagnosis is difficult with a single diagnostic method.8 Cross-sectional imaging modalities, including computed tomography (CT) and magnetic resonance imaging, play a central role in the diagnosis of small bowel tumors because they allow visualization of the entire gastrointestinal tract, as well as extramural lesions.9 Additionally, video capsule endoscopy (VCE), which is the first line diagnostic modality for small bowel bleeding, may aid in the diagnosis of small bowel tumors, although missing rates and capsule retention must be carefully considered.10,11 Device-assisted enteroscopy (DAE) allows clinicians to directly visualize small bowel tumors, identify their extent and location, obtain tissue samples, and perform therapeutic interventions.12,13 DAE is an effective diagnostic and therapeutic method, but it is more labor intensive, requires experienced endoscopists and is difficult to evaluate the entire small bowel. Despite advances in imaging and endoscopic technology, discrepancy in diagnosis occurs for each modality. Depending on the characteristics of the diagnostic modality, this is an inevitable event.
In this study, we aimed to determine the discrepancy rates between DAE and CT, and between DAE and VCE for small bowel tumors confirmed by DAE. Additionally, we analyzed the risk factors associated with concordance rates between DAE and CT, and between DAE and VCE for small bowel tumors.
This retrospective, multicenter cohort study was conducted using database of the Korean Association for the Study of Intestinal Disease web-based enteroscopy registry (https://enteroscopy.inforang.com/intro/intro.html) from 30 medical centers in South Korea between October 2015 and June 2023. Data were collected anonymously via standardized electronic case report form and managed in the Small Intestinal Research Group under the Korean Association for the Study of Intestinal Disease. Of 998 patients, 210 (21.0%) were diagnosed with small bowel tumors using DAE. A total of 193 patients diagnosed with definite small bowel tumor and underwent both DAE and CT were included in this study. Of the 193 patients, 49 underwent VCE (Fig. 1). Exclusion criteria were as follows: (1) age <18 years old; (2) no evidence of small bowel tumor in DAE and/or CT; (3) either CT or DAE was not performed; (4) uncertain diagnosis despite various diagnostic modalities; or (5) incomplete electronic medical records. The study protocol was approved by the Institutional Review Board and Hospital Research Ethics Committee of each facility (IRB number: 1-2016-0004). Written informed consent was waived.
Double (EN-450P5, T5 or EN-530T; Fujinon Inc., Saitama, Japan) and single (SIF-Q180; Olympus America Inc., Center Valley, PA, USA) balloon enteroscopes, both of which are available in South Korea, were used for enteroscopic examinations. Furthermore, for DAE using the anal approach, the patients underwent bowel preparation with at least 2 L of polyethylene glycol solution the day before the procedure. The route of DAE insertion was determined based on the location of the lesion, according to the results of previous examinations. All procedures were performed in a fluoroscopy unit, with patients undergoing conscious to deep sedation (established by endoscopists), according to each center’s sedation protocols. The PillCam SB video (SB1, SB2, and SB3; Given Imaging, Yokneam, Israel) and MiroCam (IntroMedic, Seoul, South Korea) were used for capsule endoscopy. Polyethylene glycol solution (2–4 L) was administered before the examination for cleansing and enhancement of visual clarity. Video findings were interpreted by experienced gastroenterologists at each center. We included all patients that underwent multiphasic CT and CT enterography.
The following data were collected from electronic medical records: age, sex, smoking history, alcohol history, Charlson Comorbidity Index, intestinal surgery history, indication of diagnostic test, levels of hemoglobin, albumin, transfusion of red blood cell (RBC), and the size, number, location, and final diagnosis of small bowel tumors. The Charlson Comorbidity Index was used for the assessment of comorbidity level.14
The small bowel tumors that were definite on DAE and/or CT were defined, according to the interpretation by experienced gastroenterologists and radiologists. Primary endpoint was discordance rates between DAE and CT, and between DAE and VCE. A discordance was defined when a small bowel tumor was described in DAE but its presence was not described in CT or VCE. Additionally, in DAE, it was described as a small bowel tumor, but when CT or VCE showed other findings such as ulcers/vascular lesions, it was defined as a discordance. Additionally, secondary endpoint was independent risk factors associated with the discordance between DAE and VCE, and between DAE and CT for small bowel tumors. Additionally, secondary endpoint was independent risk factors associated with the discordance between DAE and VCE, and between DAE and CT for small bowel tumors.
The mean and standard deviation or median and range were calculated for all continuous variables, as appropriate. Multivariate logistic regression analyses were performed to identify independent factors affecting discordance with adjustment for multiple variables. Variables in univariate analysis, with a p-value of ≤0.05, were included in the multivariate analysis. Moreover, a p-value of ≤0.05 was considered statistically significant. All statistical analyses were performed using Statistical Package for Social Sciences (SPSS version 23.0; SPSS Inc., Armonk, NY, USA).
The mean age of diagnosis was 54.3±13.7 years, and 57.5% of the patients were men. Thirty-nine patients (20.2%) and 47 patients (24.5%) had a history of smoking and alcohol consumption, respectively. The mean Charlson Comorbidity Index was 0.7±1.2, and 45 patients (23.3%) had a history of intestinal surgery. The indication of DAE was abnormal radiologic findings (40.9%), polyposis syndrome (17.6%), overt gastrointestinal bleeding (17.1%), occult gastrointestinal bleeding (2.1%), symptoms, such as abdominal pain, nausea, or vomiting (10.4%), intestinal obstruction (6.7%), and therapeutics (5.2%). The mean hemoglobin level was 11.4±2.6 g/dL, and the mean albumin level was 3.9±0.8 g/dL. Forty patients (20.7%) required RBC transfusion, and the mean volume of RBC was 0.8±2.1 units. Forty-four patients (22.8%) underwent per oral DAE, 141 (73.1%) underwent per anal DAE, and eight (4.1%) underwent both per oral DAE and per anal DAE. Multiphasic CT was performed in 132 (68.4%), and 61 (31.6%) underwent CT enterography. The mean size of the small bowel tumors measured on CT was 25.4±15.2 mm, and 166 patients (85.0%) had single tumor. Locations of the small bowel tumors were the duodenum (10.4%), proximal jejunum (34.2%), mid jejunum (18.7%), distal jejunum (10.9%), proximal ileum (4.7%), mid ileum (4.7%), and distal ileum (15.5%). Final diagnoses of the small bowel tumors were lymphoma (19.7%), hamartoma (18.7%), gastrointestinal stromal tumor (18.1%), ectopic pancreas (11.9%), metastasis (11.4%), lipoma (5.2%), adenocarcinoma (4.7%), benign polyp (3.6%), carcinoid (2.1%), amyloidosis (1.6%), leiomyoma (1.0%), lymphangioma (1.0%), schwannoma (0.5%), and duplication cyst (0.5%).
Of the 193 patients that underwent DAE and CT examinations, 12 (6.2%) showed discrepancy between the examinations. Male patients were more in number in a discordance group compared to those in a concordance group between DAE and CT (91.7% vs 55.2%, respectively, p=0.015). Furthermore, overt gastrointestinal bleeding was frequent in the discordance group compared to that in the concordance group between DAE and CT (41.7% vs 15.5%, respectively, p=0.035) (Table 1). Carcinoid was frequent in the discordance group compared to that in the concordance group (25.0% vs 0.6%), and amyloidosis was frequent in the discordance group compared to that in the concordance group between DAE and CT (16.7% vs 0.6%) (Table 2). Univariate logistic regression analyses were performed to determine the risk factors associated with the concordance between DAE and CT. Furthermore, female sex was positively associated with the concordance between DAE and CT in patients with small bowel tumors (odds ratio [OR], 8.910; 95% confidence interval [CI], 1.127 to 70.467; p=0.038) (Table 3). Alcohol history (OR, 0.293; 95% CI, 0.090 to 0.957; p=0.042) and overt bleeding (OR, 0.256; 95% CI, 0.076 to 0.865; p=0.028) were negatively associated with the concordance between DAE and CT in patients with small bowel tumor (Table 3). There were no significant independent risk factors in the multivariate regression analysis.
Table 1 . Baseline Characteristics Associated with Discordance between DAE and CT of Small Bowel Tumors.
Variable | Total (n=193) | Discordance (n=12) | Concordance (n=181) | p-value* |
---|---|---|---|---|
Age, yr | 54.3±13.7 | 59.4±12.4 | 54.2±16.6 | 0.288 |
Sex | 0.015 | |||
Male | 111 (57.5) | 11 (91.7) | 100 (55.2) | |
Female | 82 (42.5) | 1 (8.3) | 81 (44.8) | |
Smoking | 39 (20.2) | 3 (25.0) | 36 (19.9) | 0.711 |
Alcohol | 47 (24.4) | 6 (50.0) | 41 (23.7) | 0.074 |
Charlson Comorbidity Index | 0.7±1.2 | 0.5±1.0 | 0.7±1.4 | 0.563 |
Intestinal surgery history | 45 (23.3) | 0 | 45 (24.9) | 0.072 |
Indication of diagnostic test | ||||
Abnormal radiologic images | 79 (40.9) | 4 (33.3) | 75 (41.4) | 0.764 |
Polyposis | 34 (17.6) | 1 (8.3) | 33 (18.2) | 0.695 |
Overt bleeding | 33 (17.1) | 5 (41.7) | 28 (15.5) | 0.035 |
Occult bleeding | 4 (2.1) | 0 | 4 (2.2) | 1.000 |
Non-specific symptoms | 20 (10.4) | 2 (16.7) | 18 (9.9) | 0.359 |
Obstruction | 13 (6.7) | 0 | 13 (7.2) | 1.000 |
Others (therapeutics) | 10 (5.2) | 0 | 10 (5.5) | 1.000 |
Hemoglobin, g/dL | 11.4±2.6 | 10.9±2.7 | 11.5±2.5 | 0.448 |
Albumin, g/dL | 3.9±0.8 | 3.7±0.8 | 3.9±0.7 | 0.244 |
Red blood cell transfusion | 40 (20.7) | 4 (33.3) | 36 (19.9) | 0.276 |
Characteristics of small bowel tumor | ||||
Tumor size, mm | 25.4±15.2 | 25.0±14.0 | 25.4±17.1 | 0.947 |
Single tumor | 166 (85.0) | 10 (83.3) | 156 (86.2) | 0.970 |
Tumor location | 0.664 | |||
Duodenum | 20 (10.4) | 1 (8.3) | 19 (10.5) | |
Proximal jejunum | 66 (34.2) | 3 (25.0) | 63 (34.8) | |
Mid jejunum | 36 (18.7) | 2 (16.7) | 34 (18.8) | |
Distal jejunum | 21 (10.9) | 2 (16.7) | 19 (10.5) | |
Proximal ileum | 9 (4.7) | 0 | 9 (5.0) | |
Mid ileum | 9 (4.7) | 0 | 9 (5.0) | |
Distal ileum | 30 (15.5) | 2 (16.7) | 28 (15.5) |
Data are presented as mean±SD or number (%)..
DAE, device-assisted enteroscopy; CT, computed tomography..
*p-value for comparing discordance and accordance groups: statistically significant, p<0.05..
Table 2 . Final Diagnosis of Small Bowel Tumor According to the Discordance between DAE and CT.
Variable | Discordance (n=12) | Concordance (n=181) |
---|---|---|
Lymphoma | 3 (25.0) | 35 (19.3) |
Hamartoma | 0 | 36 (19.9) |
Gastrointestinal stromal tumor | 2 (16.7) | 33 (18.2) |
Ectopic pancreas | 0 | 23 (12.7) |
Metastasis | 0 | 22 (12.2) |
Lipoma | 0 | 10 (5.5) |
Adenocarcinoma | 0 | 9 (5.0) |
Benign polyp | 2 (16.7) | 5 (2.8) |
Carcinoid | 3 (25.0) | 1 (0.6) |
Amyloidosis | 2 (16.7) | 1 (0.6) |
Leiomyoma | 0 | 2 (1.1) |
Lymphangioma | 0 | 2 (1.1) |
Schwannoma | 0 | 1 (0.6) |
Duplication cyst | 0 | 1 (0.6) |
Data are presented as number (%)..
DAE, device-assisted enteroscopy; CT, contrast tomography..
Table 3 . Logistic Regression Analysis for Concordance between DAE and CT in Patients with Small Bower Tumor.
Variable | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|
OR (95% CI) | p-value* | OR (95% CI) | p-value* | ||
Age | 0.980 (0.944–1.017) | 0.289 | |||
Female sex | 8.910 (1.127–70.467) | 0.038 | 5.617 (0.652–48.429) | 0.116 | |
Smoking | 0.745 (0.192–2.892) | 0.670 | |||
Alcohol | 0.293 (0.090–0.957) | 0.042 | 0.498 (0.144–1.723) | 0.271 | |
Charlson Comorbidity Index (≥2) | 1.606 (0.339–7.609) | 0.551 | |||
Indication of diagnostic test | |||||
Abnormal radiologic images | 1.415 (0.411–4.871) | 0.582 | |||
Polyposis | 2.453 (0.306–19.664) | 0.398 | |||
Overt bleeding | 0.256 (0.076–0.865) | 0.028 | 0.396 (0.113–1.394) | 0.149 | |
Non-specific symptoms | 0.552 (0.112–2.719) | 0.465 | |||
Hemoglobin | 1.096 (0.865–1.368) | 0.447 | |||
Albumin | 1.586 (0.728–3.459) | 0.246 | |||
Red blood cell transfusion | 0.497 (0.142–1.741) | 0.274 | |||
Characteristics of small bowel tumor | |||||
Tumor size | 1.001 (0.961–1.044) | 0.946 | |||
Single tumor | 1.062 (0.762–1.480) | 0.723 | |||
Tumor location | |||||
Duodenum | 1.000 (reference) | ||||
Proximal jejunum | 1.105 (1.109–11.253) | 0.933 | |||
Mid jejunum | 0.895 (0.076–10.528) | 0.930 | |||
Distal jejunum | 0.500 (0.042–5.990) | 0.584 | |||
Proximal ileum | 0.999 (NA) | 0.999 | |||
Mid ileum | 0.237 (0.019–2.968) | 0.264 | |||
Distal ileum | 0.737 (0.062–8.712) | 0.809 |
DAE, device-assisted enteroscopy; CT, contrast tomography; OR, odds ratio; CI, confidence interval; NA, not applicable..
*p-value for comparing discordance and accordance groups: statistically significant, p<0.05..
Of the 49 patients that underwent DAE and VCE examinations, 13 (26.5%) showed discrepancy between the examinations. The discordance group was older compared to the concordance group between DAE and VCE (57.4 years vs 47.2 years, respectively, p=0.049) (Table 4). Overt gastrointestinal bleeding was frequent (53.8% vs 19.4%, respectively, p=0.031), hemoglobin level was lower (9.6 g/dL vs 11.7 g/dL, respectively, p=0.003), albumin level was lower (3.5 g/dL vs 4.1 g/dL, respectively, p=0.007), and RBC transfusion was frequent (69.2% vs 19.4%, respectively, p=0.002) in the discordance group compared to that of the concordance group between DAE and VCE (Table 4). Gastrointestinal stromal tumor was frequent in the discordance group compared to that of the concordance group (61.5% vs 8.3%) between DAE and VCE (Table 5). Univariate logistic regression analyses were performed to determine the risk factors associated with the concordance between DAE and VCE. Overt bleeding (OR, 0.207; 95% CI, 0.053 to 0.812; p=0.024) and RBC transfusion (OR, 0.107; 95% CI, 0.025 to 0.452; p=0.002) were negatively associated with the concordance between DAE and VCE in patients with small bowel tumors (Table 6). Higher albumin level was positively associated with the concordance between DAE and VCE in patient with small bowel tumors (OR, 3.214; 95% CI, 1.201 to 8.603; p=0.020) (Table 6). In the multivariate regression analysis, RBC transfusion was negatively associated with the concordance between DAE and VCE in patients with small bowel tumors (OR, 0.163; 95% CI, 0.026 to 1.004; p=0.050) (Table 6).
Table 4 . Baseline Characteristics Associated with Discordance between DAE and VCE of Small Bowel Tumors.
Variable | Total (n=49) | Discordance (n=13) | Concordance (n=36) | p-value* |
---|---|---|---|---|
Age, yr | 49.9±15.5 | 57.4±13.5 | 47.2±16.2 | 0.049 |
Sex | 0.333 | |||
Male | 27 (55.1) | 9 (69.2) | 18 (50.0) | |
Female | 22 (44.9) | 4 (30.8) | 18 (50.0) | |
Smoking | 7 (14.3) | 2 (15.4) | 5 (13.9) | 1.000 |
Alcohol | 12 (24.5) | 2 (15.4) | 10 (27.8) | 0.474 |
Charlson's Comorbidity Index | 0.5±1.0 | 0.6±1.1 | 0.5±0.9 | 0.657 |
Intestinal surgery history | ||||
Indication of diagnostic test | ||||
Abnormal radiologic images | 11 (22.4) | 2 (15.4) | 9 (25.0) | 0.703 |
Polyposis | 13 (26.5) | 1 (7.7) | 12 (33.3) | 0.140 |
Overt bleeding | 14 (28.6) | 7 (53.8) | 7 (19.4) | 0.031 |
Occult bleeding | 2 (4.1) | 2 (15.4) | 0 | 0.066 |
Non-specific symptoms | 4 (8.2) | 1 (7.7) | 3 (8.3) | 1.000 |
Others (therapeutics) | 5 (10.2) | 0 | 5 (13.9) | 0.306 |
Hemoglobin, g/dL | 11.1±2.7 | 9.6±3.0 | 11.7±2.2 | 0.003 |
Albumin, g/dL | 3.9±0.7 | 3.5±1.0 | 4.1±0.5 | 0.007 |
Red blood cell transfusion | 16 (32.7) | 9 (69.2) | 7 (19.4) | 0.002 |
Characteristics of small bowel tumor | ||||
Tumor size, mm | 24.0±12.5 | 30.0±14.4 | 21.8±10.9 | 0.107 |
Single tumor | 35 (71.4) | 13 (100.0) | 22 (66.1) | 0.314 |
Tumor location | 0.226 | |||
Proximal jejunum | 15 (30.6) | 3 (23.1) | 12 (33.3) | |
Mid jejunum | 15 (30.6) | 6 (46.2) | 9 (25.0) | |
Distal jejunum | 5 (10.2) | 2 (15.4) | 3 (8.3) | |
Proximal ileum | 4 (8.1) | 2 (15.4) | 2 (5.6) | |
Mid ileum | 5 (10.2) | 0 | 5 (13.9) | |
Distal ileum | 5 (10.2) | 0 | 5 (13.9) |
Data are presented as mean±SD or number (%)..
DAE, device-assisted enteroscopy; VCE, video capsule endoscopy..
*p-value for comparing discordance and accordance groups: statistically significant, p<0.05..
Table 5 . Final Diagnosis of Small Bowel Tumor According to the Discordance between DAE and VCE.
Variable | Discordance (n=13) | Concordance (n=36) |
---|---|---|
Hamartoma | 0 | 15 (41.7) |
Gastrointestinal stromal tumor | 8 (61.5) | 3 (8.3) |
Lymphoma | 1 (7.7) | 8 (22.2) |
Ectopic pancreas | 1 (7.7) | 4 (11.1) |
Benign polyp | 0 | 2 (5.6) |
Lipoma | 1 (7.7) | 1 (2.8) |
Adenocarcinoma | 0 | 1 (2.8) |
Carcinoid | 1 (7.7) | 0 |
Amyloidosis | 0 | 1 (2.8) |
Lymphangioma | 1 (7.7) | 0 |
Schwannoma | 0 | 1 (2.8) |
Data are presented as number (%)..
DAE, device-assisted enteroscopy; VCE, video capsule endoscopy..
Table 6 . Logistic Regression Analysis for Concordance between DAE and VCE in Patients with Small Bower Tumor.
Variable | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|
OR (95% CI) | p-value* | OR (95% CI) | p-value* | ||
Age | 0.957 (0.914–1.001) | 0.057 | |||
Female sex | 2.250 (0.585–8.652) | 0.238 | |||
Smoking | 0.887 (0.150–5.251) | 0.895 | |||
Alcohol | 2.115 (0.397–11.281) | 0.380 | |||
Charlson Comorbidity Index (≥2) | 2.897 (0.321–26.158) | 0.344 | |||
Indication of diagnostic test | |||||
Abnormal radiologic images | 1.833 (0.340–9.886) | 0.481 | |||
Polyposis | 6.000 (0.696–51.740) | 0.103 | |||
Overt bleeding | 0.207 (0.053–0.812) | 0.024 | 0.922 (0.141–6.024) | 0.932 | |
Non-specific symptoms | 1.091 (0.103–11.527) | 0.942 | |||
Hemoglobin | 1.470 (1.110–1.946) | 0.007 | |||
Albumin | 3.214 (1.201–8.603) | 0.020 | 2.046 (0.752–5.583) | 0.161 | |
Red blood cell transfusion | 0.107 (0.025–0.452) | 0.002 | 0.163 (0.026–1.004) | 0.050 | |
Characteristics of small bowel tumor | |||||
Tumor size (mm) | 0.946 (0.882–1.014) | 0.118 | |||
Single tumor | NA (NA) | 0.999 | |||
Tumor location | |||||
Proximal jejunum | 1.000 (reference) | ||||
Mid jejunum | 0.375 (0.073–1.920) | 0.239 | |||
Distal jejunum | 0.375 (0.042–3.355) | 0.380 | |||
Proximal ileum | 0.250 (0.024–2.577) | 0.244 | |||
Mid ileum | 0.999 (NA) | 0.999 | |||
Distal ileum | 0.999 (NA) | 0.999 |
DAE, device-assisted enteroscopy; VCE, video capsule endoscopy; OR, odds ratio; CI, confidence interval; NA, not applicable..
*p-value for comparing discordance and accordance groups: statistically significant, p<0.05..
This study was conducted with the assumption that despite advances in cross-sectional and VCE imaging, there will still be discrepancies between DAE and other modalities for small bowel tumors. In fact, the results showed that there was a discordance of 6.2% in DAE and CT, and 26.5% in DAE and VCE. Despite the development of novel techniques, the single diagnostic approach is not sufficient for a definite diagnosis of small bowel tumors.15 Cross-sectional imaging, DAE, and VCE are the most commonly used techniques for detecting small bowel tumors, and they have complementary advantages and disadvantages, and various optimal sequence of diagnostic techniques could be suggested.16,17 Therefore, identifying the discrepancy of diagnostic modalities and finding associated factors is of great help in clinical practice.18
Cross-sectional imaging, including CT and magnetic resonance imaging, could be recommended for the initial investigation of patients suspected of having small bowel tumors because it is noninvasive, as they can visualize the entire small intestine and surrounding structures.19,20 Moreover, in clinical settings, CT is the most commonly used cross-sectional imaging. However, CT enterography with luminal distention or magnetic resonance enterography without radiation is preferred for follow-up examination.16 In patients with suspected small bowel tumors, DAE could be performed for diagnostic purpose to reach histological confirmation by acquisition of biopsy sample and/or therapeutic purposes, such as hemostasis, polypectomy, or stent insertion.21 In our study, the discrepancy rate of small bowel tumors between DAE and CT was 6.2%, and the concordance between DAE and CT was quite high. In a previous study of 68 patients, small bowel tumors were detected in 58 and 61 patients using CT and DAE (discrepancy: 4.4%), respectively, which is similar to those in our study.22 Additionally, there were no significant risk factors related to the discordance between CT and DAE, including size of small bowel tumors. Nevertheless, cross-sectional imaging may have decreased the sensitivity for small-sized small bowel tumors that are <10 mm, and caution is necessary because the discrepancy between CT and VCE was relatively high for carcinoid and amyloidosis.23-25 Primary carcinoid tumor in the small bowel is often not visible due to a small size often <10 mm at initial evaluation using CT.23 Additionally, CT findings of small intestinal amyloidosis are non-specific and diverse.24,25 Additionally, in our study, patients who had CT but did not have DAE (e.g., cases thought to be small benign lesions) were excluded from the study; therefore, it should be noted that the missing rate in actual CT may be higher.
Regarding VCE, the discrepancy rate between DAE and VCE was 26.5% for small bowel tumors, which is higher than that between DAE and CT. The reason for the discrepancy between DAE and VCE is that VCE itself has some limitations due to relatively high false negative risks and false positive risks.26,27 Missing rate of VCE for solitary small bowel lesion was 10% to 12% in a previous studies because of rapid transit time in the small bowel, which is dependent on reading mode, lesion type, reader experience, and timing.28-31 Most of the small bowel tumors missed by VCE were located in the proximal jejunum because of rapid transfer velocity due to bowel peristalsis.22 Additionally, small bowel tumors cannot be reliably differentiated using VCE because the surface of benign and malignant small bowel tumors are not specific, which requires complementary diagnostic tests, such as DAE.32,33 In our study, gastrointestinal stromal tumor was frequent in the discordance group between DAE and VCE, and RBC transfusion was associated with discordance between DAE and VCE in patients with small bowel tumor in the multivariate analysis. Zagorowicz et al.34 reported the characteristics of small bowel tumors detected using VCE and identified missed tumors, and of 139 patients, two small bowel gastrointestinal stromal tumors and one mesenteric tumor were missed by VCE, which were found during a follow-up period. In patients with small bowel bleeding, they required transfusion and normal/insignificant VCE, and the risk of missing a tumor in the small bowel can be underestimated.34 Therefore, DAE should be considered as the next diagnostic approach when clinical symptoms strongly suggest small bowel bleeding. In summary, VCE itself is affected not only by rapid transition time of the small intestine but also by non-specific characteristics of small intestine tumors, resulting in a relatively high risk of false negative and positive risks. Therefore, clinicians should pay attention to when performing or interpreting VCE and consider DAE in patients with a negative VCE and high clinical suspicion (e.g., small bowel bleeding or unexplained iron deficient anemia).
This is a large multicenter study with enough sample using the Korean Association for the Study of Intestinal Disease web-based enteroscopy registry database from 30 medical centers in South Korea. Additionally, we could analyze the discrepancy rate and risk factors between DAE and CT and between DAE and VCE for small bowel tumors confirmed by DAE. Nevertheless, there are some limitations in our study. First, if DAE is requested due to suspicion of progressive disease, the actual discrepancy rate between DAE and CT may be higher in this study due to selection bias. In addition, since CT is generally taken first and DAE is often performed when abnormality of imaging is detected, selection bias may have occurred, and as a result, the discrepancy rate between DAE and CT may have been evaluated as low. Second, we could not suggest a diagnostic yield for each modality because we enrolled only patients with definite diagnosis of small bowel tumors who underwent DAE and CT. Third, the sample size of patients who underwent DAE and VCE was too small.
In conclusion, our study showed that the discrepancy rate between DAE and CT was 6.2%, and the discrepancy rate between DAE and VCE was 26.5% of small bowel tumors. Despite developments in cross-sectional imaging, including VCE and DAE modalities, discrepancies still exist. In patients with small bowel bleeding who required significant transfusion while showing insignificant VCE findings, DAE should be considered as the next diagnostic approach due to the possibility of missing a diagnosis of small bowel tumor.
This work was supported by the Soonchunhyang University Research Fund.
No potential conflict of interest relevant to this article was reported.
Conception and design: J.P., J.S.K., S.R.J. Data acquisition: J.S.K., J.H.S., K.N., S.E.K., E.S.J., J.H.K. Data analysis and interpretation: J.P. Drafting of the manuscript: J.P. Critical revision of the manuscript for important intellectual content: S.R.J. Approval of final manuscript: all authors.
Table 1 Baseline Characteristics Associated with Discordance between DAE and CT of Small Bowel Tumors
Variable | Total (n=193) | Discordance (n=12) | Concordance (n=181) | p-value* |
---|---|---|---|---|
Age, yr | 54.3±13.7 | 59.4±12.4 | 54.2±16.6 | 0.288 |
Sex | 0.015 | |||
Male | 111 (57.5) | 11 (91.7) | 100 (55.2) | |
Female | 82 (42.5) | 1 (8.3) | 81 (44.8) | |
Smoking | 39 (20.2) | 3 (25.0) | 36 (19.9) | 0.711 |
Alcohol | 47 (24.4) | 6 (50.0) | 41 (23.7) | 0.074 |
Charlson Comorbidity Index | 0.7±1.2 | 0.5±1.0 | 0.7±1.4 | 0.563 |
Intestinal surgery history | 45 (23.3) | 0 | 45 (24.9) | 0.072 |
Indication of diagnostic test | ||||
Abnormal radiologic images | 79 (40.9) | 4 (33.3) | 75 (41.4) | 0.764 |
Polyposis | 34 (17.6) | 1 (8.3) | 33 (18.2) | 0.695 |
Overt bleeding | 33 (17.1) | 5 (41.7) | 28 (15.5) | 0.035 |
Occult bleeding | 4 (2.1) | 0 | 4 (2.2) | 1.000 |
Non-specific symptoms | 20 (10.4) | 2 (16.7) | 18 (9.9) | 0.359 |
Obstruction | 13 (6.7) | 0 | 13 (7.2) | 1.000 |
Others (therapeutics) | 10 (5.2) | 0 | 10 (5.5) | 1.000 |
Hemoglobin, g/dL | 11.4±2.6 | 10.9±2.7 | 11.5±2.5 | 0.448 |
Albumin, g/dL | 3.9±0.8 | 3.7±0.8 | 3.9±0.7 | 0.244 |
Red blood cell transfusion | 40 (20.7) | 4 (33.3) | 36 (19.9) | 0.276 |
Characteristics of small bowel tumor | ||||
Tumor size, mm | 25.4±15.2 | 25.0±14.0 | 25.4±17.1 | 0.947 |
Single tumor | 166 (85.0) | 10 (83.3) | 156 (86.2) | 0.970 |
Tumor location | 0.664 | |||
Duodenum | 20 (10.4) | 1 (8.3) | 19 (10.5) | |
Proximal jejunum | 66 (34.2) | 3 (25.0) | 63 (34.8) | |
Mid jejunum | 36 (18.7) | 2 (16.7) | 34 (18.8) | |
Distal jejunum | 21 (10.9) | 2 (16.7) | 19 (10.5) | |
Proximal ileum | 9 (4.7) | 0 | 9 (5.0) | |
Mid ileum | 9 (4.7) | 0 | 9 (5.0) | |
Distal ileum | 30 (15.5) | 2 (16.7) | 28 (15.5) |
Data are presented as mean±SD or number (%).
DAE, device-assisted enteroscopy; CT, computed tomography.
*p-value for comparing discordance and accordance groups: statistically significant, p<0.05.
Table 2 Final Diagnosis of Small Bowel Tumor According to the Discordance between DAE and CT
Variable | Discordance (n=12) | Concordance (n=181) |
---|---|---|
Lymphoma | 3 (25.0) | 35 (19.3) |
Hamartoma | 0 | 36 (19.9) |
Gastrointestinal stromal tumor | 2 (16.7) | 33 (18.2) |
Ectopic pancreas | 0 | 23 (12.7) |
Metastasis | 0 | 22 (12.2) |
Lipoma | 0 | 10 (5.5) |
Adenocarcinoma | 0 | 9 (5.0) |
Benign polyp | 2 (16.7) | 5 (2.8) |
Carcinoid | 3 (25.0) | 1 (0.6) |
Amyloidosis | 2 (16.7) | 1 (0.6) |
Leiomyoma | 0 | 2 (1.1) |
Lymphangioma | 0 | 2 (1.1) |
Schwannoma | 0 | 1 (0.6) |
Duplication cyst | 0 | 1 (0.6) |
Data are presented as number (%).
DAE, device-assisted enteroscopy; CT, contrast tomography.
Table 3 Logistic Regression Analysis for Concordance between DAE and CT in Patients with Small Bower Tumor
Variable | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|
OR (95% CI) | p-value* | OR (95% CI) | p-value* | ||
Age | 0.980 (0.944–1.017) | 0.289 | |||
Female sex | 8.910 (1.127–70.467) | 0.038 | 5.617 (0.652–48.429) | 0.116 | |
Smoking | 0.745 (0.192–2.892) | 0.670 | |||
Alcohol | 0.293 (0.090–0.957) | 0.042 | 0.498 (0.144–1.723) | 0.271 | |
Charlson Comorbidity Index (≥2) | 1.606 (0.339–7.609) | 0.551 | |||
Indication of diagnostic test | |||||
Abnormal radiologic images | 1.415 (0.411–4.871) | 0.582 | |||
Polyposis | 2.453 (0.306–19.664) | 0.398 | |||
Overt bleeding | 0.256 (0.076–0.865) | 0.028 | 0.396 (0.113–1.394) | 0.149 | |
Non-specific symptoms | 0.552 (0.112–2.719) | 0.465 | |||
Hemoglobin | 1.096 (0.865–1.368) | 0.447 | |||
Albumin | 1.586 (0.728–3.459) | 0.246 | |||
Red blood cell transfusion | 0.497 (0.142–1.741) | 0.274 | |||
Characteristics of small bowel tumor | |||||
Tumor size | 1.001 (0.961–1.044) | 0.946 | |||
Single tumor | 1.062 (0.762–1.480) | 0.723 | |||
Tumor location | |||||
Duodenum | 1.000 (reference) | ||||
Proximal jejunum | 1.105 (1.109–11.253) | 0.933 | |||
Mid jejunum | 0.895 (0.076–10.528) | 0.930 | |||
Distal jejunum | 0.500 (0.042–5.990) | 0.584 | |||
Proximal ileum | 0.999 (NA) | 0.999 | |||
Mid ileum | 0.237 (0.019–2.968) | 0.264 | |||
Distal ileum | 0.737 (0.062–8.712) | 0.809 |
DAE, device-assisted enteroscopy; CT, contrast tomography; OR, odds ratio; CI, confidence interval; NA, not applicable.
*p-value for comparing discordance and accordance groups: statistically significant, p<0.05.
Table 4 Baseline Characteristics Associated with Discordance between DAE and VCE of Small Bowel Tumors
Variable | Total (n=49) | Discordance (n=13) | Concordance (n=36) | p-value* |
---|---|---|---|---|
Age, yr | 49.9±15.5 | 57.4±13.5 | 47.2±16.2 | 0.049 |
Sex | 0.333 | |||
Male | 27 (55.1) | 9 (69.2) | 18 (50.0) | |
Female | 22 (44.9) | 4 (30.8) | 18 (50.0) | |
Smoking | 7 (14.3) | 2 (15.4) | 5 (13.9) | 1.000 |
Alcohol | 12 (24.5) | 2 (15.4) | 10 (27.8) | 0.474 |
Charlson's Comorbidity Index | 0.5±1.0 | 0.6±1.1 | 0.5±0.9 | 0.657 |
Intestinal surgery history | ||||
Indication of diagnostic test | ||||
Abnormal radiologic images | 11 (22.4) | 2 (15.4) | 9 (25.0) | 0.703 |
Polyposis | 13 (26.5) | 1 (7.7) | 12 (33.3) | 0.140 |
Overt bleeding | 14 (28.6) | 7 (53.8) | 7 (19.4) | 0.031 |
Occult bleeding | 2 (4.1) | 2 (15.4) | 0 | 0.066 |
Non-specific symptoms | 4 (8.2) | 1 (7.7) | 3 (8.3) | 1.000 |
Others (therapeutics) | 5 (10.2) | 0 | 5 (13.9) | 0.306 |
Hemoglobin, g/dL | 11.1±2.7 | 9.6±3.0 | 11.7±2.2 | 0.003 |
Albumin, g/dL | 3.9±0.7 | 3.5±1.0 | 4.1±0.5 | 0.007 |
Red blood cell transfusion | 16 (32.7) | 9 (69.2) | 7 (19.4) | 0.002 |
Characteristics of small bowel tumor | ||||
Tumor size, mm | 24.0±12.5 | 30.0±14.4 | 21.8±10.9 | 0.107 |
Single tumor | 35 (71.4) | 13 (100.0) | 22 (66.1) | 0.314 |
Tumor location | 0.226 | |||
Proximal jejunum | 15 (30.6) | 3 (23.1) | 12 (33.3) | |
Mid jejunum | 15 (30.6) | 6 (46.2) | 9 (25.0) | |
Distal jejunum | 5 (10.2) | 2 (15.4) | 3 (8.3) | |
Proximal ileum | 4 (8.1) | 2 (15.4) | 2 (5.6) | |
Mid ileum | 5 (10.2) | 0 | 5 (13.9) | |
Distal ileum | 5 (10.2) | 0 | 5 (13.9) |
Data are presented as mean±SD or number (%).
DAE, device-assisted enteroscopy; VCE, video capsule endoscopy.
*p-value for comparing discordance and accordance groups: statistically significant, p<0.05.
Table 5 Final Diagnosis of Small Bowel Tumor According to the Discordance between DAE and VCE
Variable | Discordance (n=13) | Concordance (n=36) |
---|---|---|
Hamartoma | 0 | 15 (41.7) |
Gastrointestinal stromal tumor | 8 (61.5) | 3 (8.3) |
Lymphoma | 1 (7.7) | 8 (22.2) |
Ectopic pancreas | 1 (7.7) | 4 (11.1) |
Benign polyp | 0 | 2 (5.6) |
Lipoma | 1 (7.7) | 1 (2.8) |
Adenocarcinoma | 0 | 1 (2.8) |
Carcinoid | 1 (7.7) | 0 |
Amyloidosis | 0 | 1 (2.8) |
Lymphangioma | 1 (7.7) | 0 |
Schwannoma | 0 | 1 (2.8) |
Data are presented as number (%).
DAE, device-assisted enteroscopy; VCE, video capsule endoscopy.
Table 6 Logistic Regression Analysis for Concordance between DAE and VCE in Patients with Small Bower Tumor
Variable | Univariate analysis | Multivariate analysis | |||
---|---|---|---|---|---|
OR (95% CI) | p-value* | OR (95% CI) | p-value* | ||
Age | 0.957 (0.914–1.001) | 0.057 | |||
Female sex | 2.250 (0.585–8.652) | 0.238 | |||
Smoking | 0.887 (0.150–5.251) | 0.895 | |||
Alcohol | 2.115 (0.397–11.281) | 0.380 | |||
Charlson Comorbidity Index (≥2) | 2.897 (0.321–26.158) | 0.344 | |||
Indication of diagnostic test | |||||
Abnormal radiologic images | 1.833 (0.340–9.886) | 0.481 | |||
Polyposis | 6.000 (0.696–51.740) | 0.103 | |||
Overt bleeding | 0.207 (0.053–0.812) | 0.024 | 0.922 (0.141–6.024) | 0.932 | |
Non-specific symptoms | 1.091 (0.103–11.527) | 0.942 | |||
Hemoglobin | 1.470 (1.110–1.946) | 0.007 | |||
Albumin | 3.214 (1.201–8.603) | 0.020 | 2.046 (0.752–5.583) | 0.161 | |
Red blood cell transfusion | 0.107 (0.025–0.452) | 0.002 | 0.163 (0.026–1.004) | 0.050 | |
Characteristics of small bowel tumor | |||||
Tumor size (mm) | 0.946 (0.882–1.014) | 0.118 | |||
Single tumor | NA (NA) | 0.999 | |||
Tumor location | |||||
Proximal jejunum | 1.000 (reference) | ||||
Mid jejunum | 0.375 (0.073–1.920) | 0.239 | |||
Distal jejunum | 0.375 (0.042–3.355) | 0.380 | |||
Proximal ileum | 0.250 (0.024–2.577) | 0.244 | |||
Mid ileum | 0.999 (NA) | 0.999 | |||
Distal ileum | 0.999 (NA) | 0.999 |
DAE, device-assisted enteroscopy; VCE, video capsule endoscopy; OR, odds ratio; CI, confidence interval; NA, not applicable.
*p-value for comparing discordance and accordance groups: statistically significant, p<0.05.